Treatment-induced secretion of WNT16B promotes tumor growth and acquired resistance to chemotherapy: Implications for potential use of inhibitors in cancer treatment

Cancer Biology and Therapy

Volumn 14, Issue 2, 2013, Pages 90-91

  Johnson, Linda M ^a   Price, Douglas K ^a   Figg, William D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Chemotherapy resistance; Cytotoxic drugs; DNA damage response program; NFkB; Prostate cancer; Tumor microenvironment; WNT16B

Indexed keywords

DOCETAXEL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOXANTRONE; NERVE CELL ADHESION MOLECULE; UNCLASSIFIED DRUG; UVOMORULIN; WINGLESS TYPE MMTV INTEGRATION SITE FAMILY MEMBER 16B; WNT PROTEIN;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RECURRENCE; CANCER RESISTANCE; CYTOTOXICITY; DNA DAMAGE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; GENOTOXICITY; HUMAN; NONHUMAN; OVARY CANCER; PROSTATE CANCER; PROTEIN SECRETION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

CHEMOTHERAPY RESISTANCE; CYTOTOXIC DRUGS; DNA DAMAGE RESPONSE PROGRAM; NFΚB; PROSTATE CANCER; TUMOR MICROENVIRONMENT; WNT16B;

ANIMALS; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; PROSTATIC NEOPLASMS; TUMOR MICROENVIRONMENT; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84873434819     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.22636     Document Type: Article

References (6)

1. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol 2005; 205:275-92; PMID:15641020; http://dx.doi.org/10.1002/path.1706.
2. Kerbel RS, Kobayashi H, Graham CH. Intrinsic or acquired drug resistance and metastasis: are they linked phenotypesJ Cell Biochem 1994; 56:37-47; PMID:7806590; http://dx.doi.org/10.1002/jcb.240560108.
3. Davis AJ, Tannock JF. Repopulation of tumour cells between cycles of chemotherapy: a neglected factor. Lancet Oncol 2000; 1:86-93; PMID:11905673; http://dx.doi.org/10.1016/S1470-2045(00)00019-X.
4. Sun Y, Campisi J, Higano C, Beer TM, Porter P, Coleman I, et al. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med 2012; http://dx.doi.org/10.1038/ nm2890; PMID:22863786.
5. Binet R, Ythier D, Robles AI, Collado M, Larrieu D, Fonti C, et al. WNT16B is a new marker of cellular senescence that regulates p53 activity and the phosphoinositide 3-kinase/AKT pathway. Cancer Res 2009; 69:9183-91; PMID:19951988; http://dx.doi.org/10.1158/0008-5472.CAN-09-1016.
6. Fear MW, Kelsell DP, Spurr NK, Barnes MR. Wnt-16a, a novel Wnt-16 isoform, which shows differential expression in adult human tissues. Biochem Biophys Res Commun 2000; 278:814-20; PMID:11095990; http://dx.doi.org/10.1006/ bbrc.2000.3852.